Health Care·Biotechnology·$79.5B
Regeneron Pharmaceuticals (REGN) is a biotechnology company focused on developing and commercializing innovative medicines for serious diseases. With a market cap of $80 billion, it plays a significant role in the healthcare sector, particularly in areas like eye diseases, cancer, and inflammatory conditions.
EPS
Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and revenue.
Revenue
Total revenue gives insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+38.25%
Avg Stock Reaction
+0.85%
In Q4 2025, Regeneron reported an EPS of $11.44, significantly beating expectations, which reflects strong operational performance. However, the stock saw a slight decline the following day, indicating mixed market reactions despite the positive earnings surprise.
Management Promises & Guidance
Analysts are generally optimistic about Regeneron's upcoming earnings, expecting strong EPS and revenue figures. The company has a solid track record of beating earnings estimates, which adds to investor confidence.
Bull Case
If Regeneron exceeds the consensus EPS of $8.84, it could signal robust demand for its products and effective cost management, potentially driving the stock higher.
Bear Case
Conversely, if the company fails to meet expectations, particularly in revenue growth, it could raise concerns about market competition and product demand.
EPS
$8.84Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and revenue.
Revenue
$3.5BTotal revenue gives insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will the EPS exceed $8.84?
A strong EPS could reinforce investor confidence and indicate effective management and product demand.
Q2
What are the revenue figures relative to the $3.5B consensus?
Revenue performance will be crucial in assessing the company's market position and growth prospects.
Why consensus could be wrong
The consensus may be underestimating the potential for Regeneron to exceed revenue expectations due to strong demand for its existing products and new launches.
Supporting Evidence
The company has consistently beaten EPS estimates, suggesting a trend that could continue.
Strong historical performance in recent quarters indicates a solid operational foundation.
Market sentiment appears cautiously optimistic, which may not fully account for potential upside.
Key Risk
If revenue comes in above $3.5B, it could significantly shift market sentiment and expectations.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reflect the company's ability to sustain growth in a competitive biotech landscape.
Bull Confirmed If
EPS of $9.50 or higher, indicating strong operational performance.
Bear Confirmed If
Revenue falling below $3.1B, raising concerns about product demand.
Implied Move
±5.18%
Historical Avg
±5.12%
The options market is pricing in a moderate move around the earnings announcement, suggesting that investors expect some volatility.
Options price a 5.2% move but the stock has averaged only 5.1% over the last 8 quarters — setup is in-line.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Regeneron beats expectations, history suggests a potential stock increase of around 0.85%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of around 6.87% following earnings misses.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026